Argenica Therapeutics Limited (ASX:AGN)
0.0700
-0.0300 (-30.00%)
Nov 20, 2026, 2:05 PM AEDT
Argenica Therapeutics Revenue
In the fiscal year ending June 30, 2026, Argenica Therapeutics had annual revenue of 5.48M AUD with 70.66% growth. Argenica Therapeutics had revenue of 4.86M in the half year ending June 30, 2026, with 1,878.64% growth. That makes Argenica Therapeutics the 40,943rd largest company in the world by revenue and 795th in Australia.
Revenue
5.48M
Revenue Growth
+70.66%
P/S Ratio
1.64
Revenue / Employee
n/a
Employees
n/a
Market Cap
8.99M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Jun 30, 2026 | 5.48M | 2.27M | 70.66% |
| Jun 30, 2025 | 3.21M | 615.81K | 23.70% |
| Jun 30, 2024 | 2.60M | 848.04K | 48.46% |
| Jun 30, 2023 | 1.75M | 1.49M | 575.38% |
| Jun 30, 2022 | 259.10K | -36.98K | -12.49% |
| Jun 30, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| EZZ Life Science Holdings | 46.28M |
| Radiopharm Theranostics | 12.87M |
| Immuron | 7.71M |
| Proteomics International Laboratories | 3.37M |
| Imugene | 2.09M |
| Noxopharm | 1.43M |
| Cambium Bio | 1.23M |
| ReNerve | 510.36K |
Argenica Therapeutics News
- 2 months ago - Argenica Therapeutics Annual report: H2 2026 - Filings
- 3 months ago - Argenica Therapeutics Slides: Investor presentation - Filings
- 3 months ago - Argenica Therapeutics Earnings release: Q4 2026 - Filings
- 5 months ago - Argenica Therapeutics Transcript: Investor update - Transcripts
- 5 months ago - Argenica Therapeutics Slides: Investor update - Filings
- 6 months ago - Argenica Therapeutics Earnings release: Q3 2026 - Filings
- 7 months ago - Argenica Therapeutics Slides: Investor presentation - Filings
- 9 months ago - Argenica Therapeutics Quarterly report: H1 2026 - Filings